Regeneron Pharmaceuticals: Is Wall Street Finally Paying Attention?

So, Regeneron's revenue rose 1.9% from $3.68 billion in Q2 2025 to $3.75 billion, beating consensus estimate by $160 million ...

Kymera Therapeutics Announces Positive Results from BroADen Phase 1b Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader, in Patients with Moderate to Severe Atopic ...

KT-621 achieved deep STAT6 degradation across both the 100 mg and 200 mg dose groups tested, with median reductions of 94% and 98% in skin and blood, respectively, demonstrating strong translation ...

Kymera Therapeutics to Announce KT-621 BroADen Phase 1b Atopic Dermatitis Trial Results on December 8, 2025

Company to host video conference call and webcast at 8:00 a.m. ET on Monday, December 8, 2025WATERTOWN, Mass., Dec. 05, 2025 (GLOBE NEWSWIRE) ...
themarijuanaherald

Combination of CBD and CBG Resolved Severe Trigeminal Neuralgia and Postherpetic Neuropathy in Case Study

A new case study in Contemporary Clinical Dentistry documents a striking recovery in a 57-year-old woman whose trigeminal neuralgia (TN) and postherpetic neuropathy had remained debilitating despite ...